Loading...

Calliditas Therapeutics AB (publ)

CALT•NASDAQ
Healthcare
Biotechnology
$40.000
$-0.04(-0.10%)
empty-state-iconFinancials data is not available for this stockFinancials details for this stock are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Over the last four quarters, Calliditas Therapeutics AB (publ) achieved steady financial progress, growing revenue from $294.59M in Q3 2023 to $559.78M in Q2 2024. Gross profit stayed firm with margins at 90% in Q2 2024 versus 95% in Q3 2023. Operating income totaled -$34.20M in Q2 2024, maintaining a -6% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$31.50M. Net income rose to -$47.48M, with EPS at -$0.88. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;